Gilead Sciences' patent for hepatitis B treatment Vemlidy (Tenofovir) is increasing. While Dong-A ST, Daewoong Pharmaceutical, Chong Kun Dang, and Jeil succeeded in avoiding patents for the first time in March this year, Samjin, Hutechs, DongKook, and Samil have challenged the same patent for the past two months in a row. According to the pharmaceutical industry on the 23rd, Samil recently requested a passive judgment on the scope of rights for the Gilead Vemlidy salt patent. Since Samjin challenged the same patent in July, a total of four companies, including Hutechs and DongKook, have joined patent disputes in the past two months. This patent has already been successfully avoided by Dong-AST, Daewoong, Chong Kun Dan